As the world's life sciences sector rebounds, Canadian drug developers are poised to prosper. But can the sector avoid getting hollowed out by acquisitive pharma giants?
Sean Silcoff is a Technology and Life Sciences Reporter at the Globe and Mail. He covers a range of topics including Canadian tech, biotech, healthcare technology, and finance, with a focus on innovation and investment strategies. Sean is a three-time National Newspaper Award winner and is featured in various publications including Space Today and Business Times Journal.







